Allarity Therapeutics Inc
NASDAQ:ALLR

Watchlist Manager
Allarity Therapeutics Inc Logo
Allarity Therapeutics Inc
NASDAQ:ALLR
Watchlist
Price: 1.08 USD 2.86% Market Closed
Market Cap: 16.3m USD

EV/EBITDA
Enterprise Value to EBITDA

0.1
Current
-291.7
Median
4.7
Industry
Higher than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
0.1
=
Enterprise Value
-2.2m USD
/
EBITDA
-26m USD
EBITDA Growth EV/EBITDA to Growth
US
Allarity Therapeutics Inc
NASDAQ:ALLR
Average EV/EBITDA: 13.8
0.1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 751.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.7
13%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.6
17%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
10.4
6%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.6
17%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -577.1 N/A N/A
AU
CSL Ltd
ASX:CSL
17.3
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12
11%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.1 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -699.4 N/A N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
N/A
2-Years Forward
EV/EBITDA
N/A
3-Years Forward
EV/EBITDA
N/A